257 related articles for article (PubMed ID: 20040392)
21. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
22. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
23. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients.
Ozer O; Sahin FI; Aydemir F; Ozen O; Yilmaz Z; Altinörs N
Turk Neurosurg; 2009 Apr; 19(2):135-8. PubMed ID: 19431122
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.
Radaeva S; Ferreira-Gonzalez A; Sirica AE
Hepatology; 1999 May; 29(5):1453-62. PubMed ID: 10216129
[TBL] [Abstract][Full Text] [Related]
25. Metallothionein overexpression and its prognostic relevance in intrahepatic cholangiocarcinoma and extrahepatic hilar cholangiocarcinoma (Klatskin tumors).
Schmitz KJ; Lang H; Kaiser G; Wohlschlaeger J; Sotiropoulos GC; Baba HA; Jasani B; Schmid KW
Hum Pathol; 2009 Dec; 40(12):1706-14. PubMed ID: 19683330
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of HER-1 and HER-2 in extrahepatic biliary carcinoma.
Ogo Y; Nio Y; Yano S; Toga T; Koike M; Hashimoto K; Itakura M; Maruyama R
Anticancer Res; 2006; 26(1B):763-70. PubMed ID: 16739351
[TBL] [Abstract][Full Text] [Related]
27. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
28. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
[TBL] [Abstract][Full Text] [Related]
29. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
Saffari B; Jones LA; el-Naggar A; Felix JC; George J; Press MF
Cancer Res; 1995 Dec; 55(23):5693-8. PubMed ID: 7585656
[TBL] [Abstract][Full Text] [Related]
30. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
[TBL] [Abstract][Full Text] [Related]
31. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL; Estrada CR; Kapur S; Bloom KJ
Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
[TBL] [Abstract][Full Text] [Related]
32. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
33. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
34. Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.
Lee EY; Cibull ML; Strodel WE; Haley JV
Arch Pathol Lab Med; 1994 Mar; 118(3):235-9. PubMed ID: 7907854
[TBL] [Abstract][Full Text] [Related]
35. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma.
Buckley AF; Burgart LJ; Sahai V; Kakar S
Am J Clin Pathol; 2008 Feb; 129(2):245-51. PubMed ID: 18208805
[TBL] [Abstract][Full Text] [Related]
37. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in gallbladder adenocarcinoma.
Ooi A; Suzuki S; Nakazawa K; Itakura J; Imoto I; Nakamura H; Dobashi Y
Anticancer Res; 2009 Jan; 29(1):19-26. PubMed ID: 19331129
[TBL] [Abstract][Full Text] [Related]
38. EGFR expression and gene copy number in triple-negative breast carcinoma.
Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
[TBL] [Abstract][Full Text] [Related]
39. Expression of Human Epidermal Growth Factor Receptor (Her 2/neu) and Proliferative Marker Ki-67: Association with Clinicopathological Parameters in Gallbladder Carcinoma.
Pujani M; Makker I; Makker A; Jetley S; Goel MM; Jetley S
Asian Pac J Cancer Prev; 2016; 17(8):3903-9. PubMed ID: 27644637
[TBL] [Abstract][Full Text] [Related]
40. Human epidermal growth-factor receptor 2 overexpression in gastric carcinoma in Thai patients.
Sornmayura P; Rerkamnuaychoke B; Jinawath A; Euanorasetr C
J Med Assoc Thai; 2012 Jan; 95(1):88-95. PubMed ID: 22379747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
